Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial

Chien-Ying Lee; Hung-Che Shih; Min-Chien Yu; Ming-Yung Lee; Ya-Lan Chang; Ya-Yun Lai; Yi-Ching Lee; Yu-Hsiang Kuan; Chun-Che Lin

doi:10.1007/s11655-016-2531-0

Your Location：

Home >

Browse articles >

Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial

OriginalPaper | Updated：2021-08-27

- Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial
- Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial
- 中国结合医学杂志（英文版） 2017年23卷第3期页码：176-182
- Affiliations：
  
  1. Institute of Medicine, Chung Shan Medical University, Taichung,Taiwan,China
  2. Department of Pharmacy, Chung Shan Medical University Hospital, Taichung,Taiwan,China
  3. Department of Medicine, Chung Shan Medical University, Taichung,Taiwan,China
  4. Department of Integrated Chinese and Western Medicine, Chung Shan Medical University Hospital, Taichung,Taiwan,China
  5. Department of Statistics and Informatics Science, Providence University,, China,China
  6. Department of Applied Cosmetology, National Tainan Junior College of Nursing,Taiwan,China
  7. Division of Hepatogastroenterology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung,Taiwan,China
- Author bio：
- Funds：
  
  Supported by the Ministry of Economic Affairs (Contract No. 9931201029-7-1), Taiwan, China and Chung Shan Medical University (Protocol No.: CSMU-G1040001)
- DOI：10.1007/s11655-016-2531-0
  中图分类号：
- 纸质出版日期：2017，
  
  网络出版日期：2016-10-19，
Scan for full text
Lee, CY., Shih, HC., Yu, MC. et al. Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial., Chin. J. Integr. Med. 23, 176–182 (2017). https://doi.org/10.1007/s11655-016-2531-0

Chien-Ying Lee, Hung-Che Shih, Min-Chien Yu, et al. Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial[J]. Chinese Journal of Integrative Medicine, 2017,23(3):176-182.
Lee, CY., Shih, HC., Yu, MC. et al. Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial., Chin. J. Integr. Med. 23, 176–182 (2017). https://doi.org/10.1007/s11655-016-2531-0 DOI：

Chien-Ying Lee, Hung-Che Shih, Min-Chien Yu, et al. Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial[J]. Chinese Journal of Integrative Medicine, 2017,23(3):176-182. DOI： 10.1007/s11655-016-2531-0.

摘要

To investigate whether three strains of probiotics

L. acidophilus

L. rhamnosus

and L. sporogenes

had signifificant inhibitive effects on Helicobacter pylori (H. pylori). This is a 4-week

randomly assigned

parallel-group

doubled-blind

and placebo-controlled study. Fifty patients with a positive H. pylori infection urea breath test (△UBT) result > 10% and without ulcer symptoms were randomized into a treatment group and a placebo group by a computer generated allocation sheet with 1:1. These subjects took one capsule of probiotics or placebo twice daily. The primary measurement was the change in △UBT values. The △UBT values during the 4-week treatment period and the 2-week follow-up period were not signifificantly different between the treatment group and the placebo group

indicating that the inhibitive effects on H. pylori were comparable between both groups. The monocyte count (%) was 5.77±1.11 in the treatment group versus 5.09±1.12 in the placebo group (P=0.044)

and the basophile count was 0.55±0.32 in the treatment group versus 0.36±0.23 in the placebo group (P=0.024) at week 2 of the treatment period

both of which reached statistical signifificance. The monocyte count was 5.75±1.26 in the treatment group and 4.72±0.99 in the placebo group at the end of the follow-up period (P=0.003). There was no signifificant inhibitive effects of the three probiotic strains (L. acidophilus

L. rhamnosus

and L. sporogenes) on H. pylori. Probiotics can not play the same role as antibiotics in the eradication of H. pylori

the role of probiotics is likely to be important as adjuvant to the triple or quadruple therapy for H. pylori

especially in resistance cases.

Abstract

To investigate whether three strains of probiotics

L. acidophilus

L. rhamnosus

and L. sporogenes

had signifificant inhibitive effects on Helicobacter pylori (H. pylori). This is a 4-week

randomly assigned

parallel-group

doubled-blind

indicating that the inhibitive effects on H. pylori were comparable between both groups. The monocyte count (%) was 5.77±1.11 in the treatment group versus 5.09±1.12 in the placebo group (P=0.044)

and the basophile count was 0.55±0.32 in the treatment group versus 0.36±0.23 in the placebo group (P=0.024) at week 2 of the treatment period

L. rhamnosus

and L. sporogenes) on H. pylori. Probiotics can not play the same role as antibiotics in the eradication of H. pylori

the role of probiotics is likely to be important as adjuvant to the triple or quadruple therapy for H. pylori

especially in resistance cases.

关键词

probioticsHelicobacter pyloriurea breath testrandomized double-blind placebo-controlled trial

Keywords

probioticsHelicobacter pyloriurea breath testrandomized double-blind placebo-controlled trial

references

Del Giudice G, Michetti P. Inflammation, immunity and vaccines for Helicobacter pylori. Helicobacter 2004;9 (Suppl 1):23–28.

Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr 2007;137: 812S-818S.

Dzierzanowska-Fangrat K, Lehours P, Megraud F, Dzierzanowska D. Diagnosis of Helicobacter pylori infection. Helicobacter 2006;11 (Suppl):6–13.

Koletzko S, Konstantopoulos N, Bosman D, Feydt-Schmidt A, van der Ende A, Kalach N. Evaluation of a novel monoclonal enzyme immunoassay for detection of Helicobacter pylori antigen in stool from children. Gut 2003;52: 804–806.

Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24: 1587–1600.

Coelho LG, Silva AE, Coelho MC, Penna FG, Ferreira RO, Elisa SC. Does low dose 13C-urea breath test maintain a satisfactory accuracy in diagnosing Helicobacter pylori infection? Arq Gastroenterol 2011;48: 104–108.

Mauro M, Radovic V, Zhou P. 13C urea breath test for (Helicobacter pylori): determination of the optimal cut-offpoint in a Canadian community population. Can J Gastroenterol 2006;20: 770–774.

Mion F, Rosner G, Rousseau M. 13C-urea breath test for Helicobacter pylori: cut-offpoint determination by cluster analysis. Clin Sci (Lond) 1997;93: 3–6.

Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994;29: 1070–1075.

Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Metaanalysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28: 868–877.

Hasni S, Ippolito A, Illei GG. Helicobacter pylori and autoimmune diseases. Oral Dis 2011;17: 621–627.

Aiba Y, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acidmediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998;93: 2097–2101. practice: what are the risks? Am J Clin Nutr 2006;83: 1256–1264; quiz 1446-1257.

Michetti P, Dorta G, Wiesel PH, Brassart D, Verdu E, Herranz M. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999;60: 203–209.

Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009;14: 97–107.

Tsai CC, Huang LF, Lin CC, Tsen HY. Antagonistic activity against Helicobacter pylori infection in vitro by a strain of Enterococcus faecium TM39. Int J Food Microbiol 2004;96: 1–12.

Medeiros JA, Goncalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 2011;30: 555–559.

Myllyluoma E, Ahonen AM, Korpela R. Effects of multispecies probiotic combination on Helicobacter pylori infection in vitro. Clin Vaccine Immun: 2008;15: 1472–1482.

Lactobacillus sporogenes. Altern Med Rev 2002;7: 340–342.

Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003;22: 360–366.

Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev 2003;8: 143–155.

Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19: 449–490.

Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection—a critical review. Aliment Pharmacol Ther 2004;20: 1001–1017.

Canducci F, Cremonini F, Armuzzi AD, Caro S, Gabrielli M, Santarelli L. Probiotics and Helicobacter pylori eradication. Dig Liver Dis 2002;34 (Suppl 2):S81–S83.

Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000;14: 1625–1629.

Ziemniak W. Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol 2006;57 (Suppl 3):123–141.

Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23: 1077–1086.

Montalto M, Curigliano V, Santoro L, Vastola M, Cammarota G, Manna R. Management and treatment of lactose malabsorption. World J Gastroenterol 2006;12: 187–191.

Cerezuela R, Cuesta A, Meseguer J, Angeles Esteban M. Effects of inulin on gilthead seabream (Sparus aurata L.) innate immune parameters. Fish Shellfish Immunol 2008;24: 663–668.

Mitchell P, Germain C, Fiori PL, Khamri W, Foster GR, Ghosh S. Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development. Infect Immun 2007;75: 810–819.

Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull 1998;54: 139–150.

Veckman V, Miettinen M, Matikainen S, Lande R, Giacomini E, Coccia EM. Lactobacilli and streptococci induce inflammatory chemokine production in human macrophages that stimulates Th1 cell chemotaxis. J Leukoc Biol 2003;74: 395–402.

Zhang L, Su P, Henriksson A, Mitchell H. Investigation of the immunomodulatory effects of Lactobacillus casei and Bifidobacterium lactis on Helicobacter pylori infection. Helicobacter 2008;13: 183–190.

O’Hara AM, Shanahan F. Mechanisms of action of probiotics in intestinal diseases. Sci World J 2007;7: 31–46.

Karttunen TJ, Niemela S, Kerola T. Blood leukocyte differential in Helicobacter pylori infection. Dig Dis Sci 1996;41: 1332–1336.

Permin H, Norgaard A, Norn S, Andersen LP, Nielsen H. IgEmediated immune response to Helicobacter pylori examined by basophil histamine release in patients with dyspepsia. Inflamm Res 2000;49 (Suppl 1):S29–S30.

Crabtree JE, Peichl P, Wyatt JI. Gastric interleukin-8 and IgA IL-8 autoantibodies in Helicobacter pylori infection. Scand J Immunol 1993;37: 65–70.

Nishioka H, Baesso I, Semenzato G, Trentin L, Rappuoli R, Del Giudice G. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. Eur J Immunol 2003;33: 840–849.

Farnworth ER. The evidence to support health claims for probiotics. J Nutr 2008;138: 1250S-1254S.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

In vitro bactericidal activity of jinghua weikang capsule (荆花胃康胶丸) and its individual herb Chenopodium Ambrosioides L. against antibiotic-resistant Helicobacter Pylori

Effect of volatile oil of amomum on expressions of platelet activating factor and mastocarcinoma-related peptide in the gastric membrane of chronic gastritis patients with helicobacter-pylori infection

Efficacy observation on Yunnan Baiyao ( ) combined with antibiotics in treating Helicobacter pylori related duodenal ulcer) combined with antibiotics in treating Helicobacter pylori related duodenal ulcer

Study on therapeutic mechanism of Xilei powder for peptic ulcer) for peptic ulcer

Innovative Perspectives of Integrated Chinese Medicine on H. pylori